Human papillomavirus type 2 (HPV-2) (HPV-2)

Human papillomavirus type 2 (HPV-2) is a non-enveloped, double-stranded DNA virus belonging to the Alphapapillomavirus genus (NCBI Taxonomy ID: 10568). It is the primary causative agent of verruca vulgaris, or common warts, which are benign proliferative lesions of the cutaneous epithelium (StatPearls, 'Verruca Vulgaris'). The virus infects the basal keratinocytes through micro-abrasions and expresses early proteins (E1-E7) to hijack host cell replication machinery and late proteins (L1-L2) for capsid assembly (IARC Monographs, Volume 90). Unlike high-risk mucosal types, HPV-2 is generally considered low-risk as it is not typically associated with malignancy (PubMed, PMID: 12657377). Therapeutic strategies against HPV-2 involve the use of keratolytics like salicylic acid to remove infected tissue or immunomodulators like imiquimod to enhance the host's antiviral response (PubChem, CID 338). While no specific HPV-2 antiviral drug exists, broad-spectrum agents like cidofovir have shown efficacy by inhibiting viral DNA polymerase (PubMed, PMID: 10831015).

Other names

HPV2Alphapapillomavirus 4Human papillomavirus 2

The primary mechanisms of action for drugs targeting HPV-2 infections include keratolysis, immune system modulation, and inhibition of DNA synthesis. Salicylic acid promotes the desquamation of hyperkeratotic epithelium by reducing keratinocyte adhesion (PubChem, CID 338). Imiquimod functions as an agonist for Toll-like receptor 7 (TLR7), triggering the release of pro-inflammatory cytokines that activate a cell-mediated immune response against the virus (StatPearls, 'Imiquimod'). Antiviral agents like cidofovir act as nucleotide analogs that selectively inhibit viral DNA polymerase, thereby halting viral replication (PubMed, PMID: 10831015).